Repare Therapeutics Inc is a pioneering force in the field of precision oncology, focusing on the development of innovative cancer treatments. With a strong foundation in synthetic lethality, the company leverages its cutting-edge SNIPRx platform to identify and advance a portfolio of therapies aimed at combating genomic instability and DNA damage repair deficiencies. Its flagship product, Camonsertib, targets solid tumors with specific genetic alterations, showcasing the company's commitment to addressing unmet medical needs. Based in Canada, Repare Therapeutics is also exploring novel drug candidates and collaborations to expand its impact on cancer care.